Response to “Systemic Bevacizumab for Hereditary Hemorrhagic Telangiectasia: Considerations from Observational Studies”

Abstract

Get full access to this article

View all access options for this article.

References

Hsu

Bai

Cheng

Chen

. Medical treatment for epistaxis in hereditary hemorrhagic telangiectasia: a meta-analysis [published online September 11, 2018]. Otolaryngol Head Neck Surg. doi:10.1177/0194599818797316

Al-Samkari

Kritharis

Rodriguez-Lopez

Kuter

. Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia [published online September 6, 2018]. J Intern Med. doi:10.1111/joim.12832

Dupuis-Girod

Ginon

Saurin

et al . Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA. 2012;307:948-955.

Guilhem

Fargeton

Simon

et al . Intravenous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): a retrospective study of 46 patients. PLoS One. 2017;12:e0188943.

Iyer

Apala

Pannu

et al . Intravenous bevacizumab for refractory hereditary hemorrhagic telangiectasia-related epistaxis and gastrointestinal bleeding. Mayo Clin Proc. 2018;93:155-166.